Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis

Matthew T Kitson, Christoph M Sarrazin, Pierluigi L Toniutto, Guy D Eslick, Stuart Keith Roberts

Research output: Contribution to journalArticleResearchpeer-review

27 Citations (Scopus)

Abstract

Background Aims The baseline 25-hydroxyvitamin D (25[OH]D) level has recently been reported to be an independent predictor of sustained virologic response (SVR) to treatment with pegylated interferon (PEG-IFN) plus ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. However, studies have yielded inconsistent results. Thus, we conducted a systematic review and meta-analysis to clarify any association between baseline 25(OH)D level and SVR in HCV therapy. Methods Two reviewers searched four electronic databases (Medline, Embase, PubMed, and Cochrane trials register) and relevant international conference proceedings up to March 2014 for studies treating chronic HCV infection with PEG-IFN plus RBV where baseline 25(OH)D level was tested. Studies involving patients with HIV co-infection, previous liver transplantation or those receiving vitamin D supplementation were excluded. The mean baseline 25(OH)D level was compared between those who achieved and those who failed to achieve SVR. Pooled standard difference in mean 25(OH)D level, odds ratios (OR) and 95 confidence intervals (CI) were calculated with the Comprehensive Meta-Analysis software (version 2.0) using a random effects model. Results 11 studies comprising 2605 patients were included in the meta-analysis. There was no significant association between the baseline mean 25(OH)D level and SVR (OR 1.44, 95 CI 0.92-2.26; p = 0.11), either in patients infected with genotypes 1/4/5 (OR 1.48, 95 CI 0.94-2.34; p = 0.09) or genotypes 2/3 (OR 1.51, 95 CI 0.26-8.87; p = 0.65). Conclusions The baseline 25(OH)D level is not associated with SVR to PEG-IFN plus RBV therapy in chronic HCV infection, regardless of genotype. Any effect of vitamin D supplementation on SVR is yet to be definitively determined.
Original languageEnglish
Pages (from-to)1247 - 1252
Number of pages6
JournalJournal of Hepatology
Volume61
Issue number6
DOIs
Publication statusPublished - 2014

Cite this

@article{cd67a6e007c24db2a3c12e13e92e3c1c,
title = "Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis",
abstract = "Background Aims The baseline 25-hydroxyvitamin D (25[OH]D) level has recently been reported to be an independent predictor of sustained virologic response (SVR) to treatment with pegylated interferon (PEG-IFN) plus ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. However, studies have yielded inconsistent results. Thus, we conducted a systematic review and meta-analysis to clarify any association between baseline 25(OH)D level and SVR in HCV therapy. Methods Two reviewers searched four electronic databases (Medline, Embase, PubMed, and Cochrane trials register) and relevant international conference proceedings up to March 2014 for studies treating chronic HCV infection with PEG-IFN plus RBV where baseline 25(OH)D level was tested. Studies involving patients with HIV co-infection, previous liver transplantation or those receiving vitamin D supplementation were excluded. The mean baseline 25(OH)D level was compared between those who achieved and those who failed to achieve SVR. Pooled standard difference in mean 25(OH)D level, odds ratios (OR) and 95 confidence intervals (CI) were calculated with the Comprehensive Meta-Analysis software (version 2.0) using a random effects model. Results 11 studies comprising 2605 patients were included in the meta-analysis. There was no significant association between the baseline mean 25(OH)D level and SVR (OR 1.44, 95 CI 0.92-2.26; p = 0.11), either in patients infected with genotypes 1/4/5 (OR 1.48, 95 CI 0.94-2.34; p = 0.09) or genotypes 2/3 (OR 1.51, 95 CI 0.26-8.87; p = 0.65). Conclusions The baseline 25(OH)D level is not associated with SVR to PEG-IFN plus RBV therapy in chronic HCV infection, regardless of genotype. Any effect of vitamin D supplementation on SVR is yet to be definitively determined.",
author = "Kitson, {Matthew T} and Sarrazin, {Christoph M} and Toniutto, {Pierluigi L} and Eslick, {Guy D} and Roberts, {Stuart Keith}",
year = "2014",
doi = "10.1016/j.jhep.2014.08.004",
language = "English",
volume = "61",
pages = "1247 -- 1252",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "6",

}

Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. / Kitson, Matthew T; Sarrazin, Christoph M; Toniutto, Pierluigi L; Eslick, Guy D; Roberts, Stuart Keith.

In: Journal of Hepatology, Vol. 61, No. 6, 2014, p. 1247 - 1252.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis

AU - Kitson, Matthew T

AU - Sarrazin, Christoph M

AU - Toniutto, Pierluigi L

AU - Eslick, Guy D

AU - Roberts, Stuart Keith

PY - 2014

Y1 - 2014

N2 - Background Aims The baseline 25-hydroxyvitamin D (25[OH]D) level has recently been reported to be an independent predictor of sustained virologic response (SVR) to treatment with pegylated interferon (PEG-IFN) plus ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. However, studies have yielded inconsistent results. Thus, we conducted a systematic review and meta-analysis to clarify any association between baseline 25(OH)D level and SVR in HCV therapy. Methods Two reviewers searched four electronic databases (Medline, Embase, PubMed, and Cochrane trials register) and relevant international conference proceedings up to March 2014 for studies treating chronic HCV infection with PEG-IFN plus RBV where baseline 25(OH)D level was tested. Studies involving patients with HIV co-infection, previous liver transplantation or those receiving vitamin D supplementation were excluded. The mean baseline 25(OH)D level was compared between those who achieved and those who failed to achieve SVR. Pooled standard difference in mean 25(OH)D level, odds ratios (OR) and 95 confidence intervals (CI) were calculated with the Comprehensive Meta-Analysis software (version 2.0) using a random effects model. Results 11 studies comprising 2605 patients were included in the meta-analysis. There was no significant association between the baseline mean 25(OH)D level and SVR (OR 1.44, 95 CI 0.92-2.26; p = 0.11), either in patients infected with genotypes 1/4/5 (OR 1.48, 95 CI 0.94-2.34; p = 0.09) or genotypes 2/3 (OR 1.51, 95 CI 0.26-8.87; p = 0.65). Conclusions The baseline 25(OH)D level is not associated with SVR to PEG-IFN plus RBV therapy in chronic HCV infection, regardless of genotype. Any effect of vitamin D supplementation on SVR is yet to be definitively determined.

AB - Background Aims The baseline 25-hydroxyvitamin D (25[OH]D) level has recently been reported to be an independent predictor of sustained virologic response (SVR) to treatment with pegylated interferon (PEG-IFN) plus ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. However, studies have yielded inconsistent results. Thus, we conducted a systematic review and meta-analysis to clarify any association between baseline 25(OH)D level and SVR in HCV therapy. Methods Two reviewers searched four electronic databases (Medline, Embase, PubMed, and Cochrane trials register) and relevant international conference proceedings up to March 2014 for studies treating chronic HCV infection with PEG-IFN plus RBV where baseline 25(OH)D level was tested. Studies involving patients with HIV co-infection, previous liver transplantation or those receiving vitamin D supplementation were excluded. The mean baseline 25(OH)D level was compared between those who achieved and those who failed to achieve SVR. Pooled standard difference in mean 25(OH)D level, odds ratios (OR) and 95 confidence intervals (CI) were calculated with the Comprehensive Meta-Analysis software (version 2.0) using a random effects model. Results 11 studies comprising 2605 patients were included in the meta-analysis. There was no significant association between the baseline mean 25(OH)D level and SVR (OR 1.44, 95 CI 0.92-2.26; p = 0.11), either in patients infected with genotypes 1/4/5 (OR 1.48, 95 CI 0.94-2.34; p = 0.09) or genotypes 2/3 (OR 1.51, 95 CI 0.26-8.87; p = 0.65). Conclusions The baseline 25(OH)D level is not associated with SVR to PEG-IFN plus RBV therapy in chronic HCV infection, regardless of genotype. Any effect of vitamin D supplementation on SVR is yet to be definitively determined.

UR - http://www.sciencedirect.com/science/article/pii/S0168827814005431

U2 - 10.1016/j.jhep.2014.08.004

DO - 10.1016/j.jhep.2014.08.004

M3 - Article

VL - 61

SP - 1247

EP - 1252

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 6

ER -